CMS releases questions for Provenge meeting

The Centers for Medicare & Medicaid Services has posted a list of questions for its Nov. 17 coverage-analysis meeting on Dendreon's new prostate cancer vaccine Provenge; the focus is on the treatment's efficacy, but several questions also address off-label use. Report